Lastly, a phase-I trial (NCT03708328) examines single-agent RO7121661, a bsAb binding to both TIM-3 and PD-1, in patients with different types of cancers, including melanoma, while NCT05451407 is scheduled to test the efficacy and safety of TQB2618 injection (humanized IgG4 mAb targeting TIM-3) together with terprizumab (anti-PD-1) in 50 patients with advanced melanoma. Here, HAVCR2 is linked to melanoma.